ClassID:

95368

C07D471/18 - CPC Classification

Classification description:

Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups  -  in which the condensed system contains three hetero rings Bridged systems

Recent Application in this class:
#1
20260138998
2026-05-21

GLP-1 RECEPTOR AGONISTS AND METHODS OF USE

#2
20260137703
2026-05-21

2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER

#3
20260116881
2026-04-30

KIF MODULATOR COMPOUNDS AND METHODS OF USE

#4
20260097037
2026-04-09

FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT

#5
20260092066
2026-04-02

NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE

#6
20260070909
2026-03-12

GPR65 MODULATORS

#7
20260055109
2026-02-26

IBOGAINE COMPOUNDS FOR TREATING BRAIN DISORDERS

#8
20260049061
2026-02-19

SMALL MOLECULES AS KCNQ2/3 (KV7.2/3) CHANNEL ACTIVATORS AND THEIR MEDICAL USE THEREOF

#9
20260042761
2026-02-12

ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS

#10
20260035368
2026-02-05

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF

#11
20250361213
2025-11-27

1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF

#12
20250340569
2025-11-06

INHIBITORS OF KIF18A AND USES THEREOF

#13
20250320213
2025-10-16

Nitrogen-Containing Heterocyclic Compounds

#14
20250313562
2025-10-09

Substituted tricyclic ligands for FK506-binding proteins for treatment of diseases

#15
20250304572
2025-10-02

HETEROCYCLIC GLP-1R AGONISTS

#16
20250296933
2025-09-25

METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS

#17
20250289822
2025-09-18

SOLID FORMS OF HIV INTEGRASE INHIBITORS

#18
20250243219
2025-07-31

MACROCYCLIC COMPOUNDS AND USES THEREOF

#19
20250230163
2025-07-17

SOLID FORMS OF HIV INTEGRASE INHIBITORS

#20
20250230162
2025-07-17

METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS

#21
20250230161
2025-07-17

POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA

#22
20250197398
2025-06-19

Varenicline Related Compounds and Methods for Treating Diseases and Conditions Including Tobacco Use Disorder

#23
20250179079
2025-06-05

HEXAHYDROPYRIDO[4,3-B]INDOLYL KETONE DERIVATIVES USEFUL AS CGAS MODULATORS

#24
20250179031
2025-06-05

PROTEASOME ENHANCERS AND USES THEREOF

#25
20250154111
2025-05-15

1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF

#26
20250129075
2025-04-24

PRODUCTION METHOD FOR T CELLS OR NK CELLS, MEDIUM FOR CULTURING T CELLS OR NK CELLS, METHOD FOR CULTURING T CELLS OR NK CELLS, METHOD FOR MAINTAINING UNDIFFERENTIATED STATE OF UNDIFFERENTIATED T CELLS, AND GROWTH-ACCELERATING AGENT FOR T CELLS OR NK CELLS

#27
20250122213
2025-04-17

OPIOID RECEPTOR MODULATORS

#28
20250120989
2025-04-17

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF

#29
20250115619
2025-04-10

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#30
20250115597
2025-04-10

TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF

#31
20250090696
2025-03-20

MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF

#32
20240383852
2024-11-21

ANTI-VIRAL COMPOUNDS

#33
20240368173
2024-11-07

TRICYCLIC GPR65 MODULATORS

#34
20240352015
2024-10-24

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE

#35
20240327410
2024-10-03

Monoacylglycerol Lipase Modulators

#36
20240287073
2024-08-29

4-SUBSTITUED CYTISINE ANALOGUES

#37
20240246975
2024-07-25

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF

#38
20240246902
2024-07-25

PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE

#39
20240238285
2024-07-18

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#40
20240228494
2024-07-11

COMPOUNDS

#41
20240228459
2024-07-11

WEE1 INHIBITORS AND USES THEREOF

#42
20240217983
2024-07-04

GPR119 AGONISTS

#43
20240197726
2024-06-20

NOVEL TETRAHYDROISOQUINOLINE ALKALOID COMPOUND CONTAINING MACROCYCLE

#44
20240190821
2024-06-13

SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF

#45
20240174642
2024-05-30

HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING

#46
20240174616
2024-05-30

HDAC6 INHIBITORS AND USES THEREOF

#47
20240150339
2024-05-09

Compounds and Their Use as PDE4 Activators

#48
20240132499
2024-04-25

FUSED PYRROLINES WHICH ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS

#49
20240124448
2024-04-18

TYK2 inhibitors and compositions and methods thereof

#50
20240101571
2024-03-28

NLRP3 MODULATORS

#51
20240067650
2024-02-29

MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF

#52
20240059688
2024-02-22

CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER

#53
20240051961
2024-02-15

N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER

#54
20240043382
2024-02-08

MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES

#55
20240010635
2024-01-11

NOVEL INDIRUBIN DERIVATIVES HAVING HETEROBICYCLIC MOIETIES AND THE USE THEREOF

#56
20230365563
2023-11-16

QUINAZOLINE COMPOUND AND APPLICATION THEREOF

#57
20230357270
2023-11-09

TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES

#58
20230303571
2023-09-28

Ibogaine-related compounds and corresponding methods

#59
20230285407
2023-09-14

Vareniciline compound and process of manufacture thereof

#60
20230285406
2023-09-14

Vareniciline compound and process of manufacture thereof

#61
20230285404
2023-09-14

VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF

#62
20230271976
2023-08-31

Opioid receptor modulators

#63
20230255976
2023-08-17

Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates

#64
20230242531
2023-08-03

Monoacylglycerol lipase modulators

#65
20230227454
2023-07-20

Polycyclic carbamoylpyridone derivative

#66
20230212170
2023-07-06

INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF

#67
20230212168
2023-07-06

ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF

#68
20230203061
2023-06-29

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

#69
20230203038
2023-06-29

4-substitued cytisine analogues

#70
20230183258
2023-06-15

NLRP3 MODULATORS

#71
20230167114
2023-06-01

MACROCYCLIC JAK INHIBITOR AND USE THEREOF

#72
20230151010
2023-05-18

CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0 2·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE

#73
20230126252
2023-04-27

Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors

#74
20230087744
2023-03-23

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#75
20230058729
2023-02-23

MACROCYCLES AS FACTOR XIA INHIBITORS

#76
20230056135
2023-02-23

MONOMER AND MULTIMERIC ANTI-HBV AGENTS

#77
20230047648
2023-02-16

Method for Isolation of Cytisine

#78
20230040709
2023-02-09

Tridentate macrocyclic compounds

#79
20230027019
2023-01-26

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

#80
20230012600
2023-01-19

BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF

#81
20230002409
2023-01-05

MACROCYCLIC FLU ENDONUCLEASE INHIBITORS

#82
20220380369
2022-12-01

CYTISINE SALTS

#83
20220315583
2022-10-06

Monoacylglycerol lipase modulators

#84
20220281887
2022-09-08

Spirocyclic lactams as JAK2 V617F inhibitors

#85
20220281868
2022-09-08

MACROCYCLIC DERIVATIVES AS FACTOR XIA INHIBITORS

#86
20220249508
2022-08-11

Varenicline compound and process of manufacture thereof

#87
20220233525
2022-07-28

Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections

#88
20220204508
2022-06-30

Macrocyclic derivatives acting as XIa factor inhibitor

#89
20220194942
2022-06-23

3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same

#90
20220153741
2022-05-19

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C

#91
20220144836
2022-05-12

NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE

#92
20220144835
2022-05-12

ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS

#93
20220135565
2022-05-05

BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF

#94
20220119391
2022-04-21

Macrocyclic compound and use thereof

#95
20220041601
2022-02-10

PYRIMIDINONES AS FACTOR XIA INHIBITORS

#96
20220017867
2022-01-20

Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells

#97
20220009935
2022-01-13

Inhibitors of GLI1 as therapeutic agents

#98
20220002314
2022-01-06

PIPERAZINYL AND PIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING ACTIVITY AGAINST PAIN

#99
20220002301
2022-01-06

Aminopyrimidinyl derivatives

#100
20210371423
2021-12-02

Ibogaine-related compounds and corresponding methods

#101
20210371422
2021-12-02

MORPHINAN DERIVATIVE

#102
20210361668
2021-11-25

Fused pentacyclic imidazole derivatives as modulators of TNF activity

#103
20210361662
2021-11-25

Tricyclic heterocycle compounds useful as HIV integrase inhibitors

#104
20210355126
2021-11-18

Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors

#105
20210355122
2021-11-18

Pyrazolopyridine compounds for the treatment of autoimmune disease

#106
20210300929
2021-09-30

Method for isolation of cytisine

#107
20210292336
2021-09-23

NLRP3 modulators

#108
20210292324
2021-09-23

Compounds and compositions for the treatment of cystic fibrosis

#109
20210277019
2021-09-09

Heterocyclic compounds and their use in preventing or treating bacterial infections

#110
20210267989
2021-09-02

Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates

#111
20210214356
2021-07-15

3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-C]pyridine compounds and medicaments using same

#112
20210155637
2021-05-27

Fused pentacyclic imidazole derivatives

#113
20210122760
2021-04-29

Macrocyclic deaza-purinones for the treatment of viral infections

#114
20210122751
2021-04-29

Polycyclic carbamoylpyridone derivative

#115
20210053988
2021-02-25

Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections

#116
20200405887
2020-12-31

Macrocyclic ligands with pendant chelating moieties and complexes thereof

#117
20200392157
2020-12-17

Calpain modulators and therapeutic uses thereof

#118
20200369663
2020-11-26

Compounds and compositions for the treatment of cystic fibrosis

#119
20200361938
2020-11-19

Method for isolation of cytisine

#120
20200317689
2020-10-08

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

#121
20200308174
2020-10-01

HDAC6 inhibitors, with improved solubility and their uses

#122
20200215062
2020-07-09

Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections

#123
20200190099
2020-06-18

Pyrimidine derivative compound, pharmaceutically acceptable salt thereof, preparation process thereof, and pharmaceutical composition using the same

#124
20200190085
2020-06-18

Cytisine salts

#125
20200188397
2020-06-18

Biheteroaryl compounds and uses thereof

#126
20200172544
2020-06-04

4-substitued cytisine analogues

#127
20200171029
2020-06-04

BIHETEROARYL COMPOUNDS AND USES THEREOF

#128
20200165251
2020-05-28

Compounds and methods for treating bacterial infections

#129
20200157102
2020-05-21

Methods for preparing bis-tetrahydroisoquinoline-containing compounds

#130
20200157101
2020-05-21

Reinforced macrocyclic ligands, complexes thereof, and uses of same

#131
20200123155
2020-04-23

Macrocyclic ligands with picolinate group(s), complexes thereof and also medical uses thereof

#132
20200102311
2020-04-02

Monoacylglycerol Lipase Modulators

#133
20200095252
2020-03-26

Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof

#134
20200087312
2020-03-19

Macrocycles as factor XIA inhibitors

#135
20200071340
2020-03-05

Pyrimido-diazepinone compounds and methods of treating disorders

#136
20200062757
2020-02-27

Macrocyclic ligands with pendant chelating moieties and complexes thereof

#137
20200055855
2020-02-20

Synthesis of NIR fluorescent probe

#138
20200055854
2020-02-20

Pyrimidinones as factor XIA inhibitors

#139
20200010419
2020-01-09

Nanohoop compound embodiments comprising meta-substitution and molecular systems comprising the same

#140
20200002339
2020-01-02

Compositions and methods for making terpenoid indole alkaloids

#141
20190367535
2019-12-05

Fused pentacyclic imidazole derivatives

#142
20190330222
2019-10-31

Macrocyclic deaza-purinones for the treatment of viral infections

#143
20190240217
2019-08-08

Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

#144
20190177324
2019-06-13

Beta-lactamase inhibitors

#145
20190134028
2019-05-09

Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections

#146
20190112311
2019-04-18

Therapeutic compound for pain and synthesis thereof

#147
20190097157
2019-03-28

Polycyclic compound and organic electroluminescence device including the same

#148
20190092787
2019-03-28

Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections

#149
20190084998
2019-03-21

Pyrimido-diazepinone compounds and methods of treating disorders

#150
20190048009
2019-02-14

Methods for preparing bis-tetrahydroisoquinoline-containing compounds

#151
20190046526
2019-02-14

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#152
20190023705
2019-01-24

Macrocylic ligands with picolinate group(s), complexes thereof and also medical uses thereof

#153
20180327406
2018-11-15

Therapeutic compounds for pain and synthesis thereof

#154
20180327405
2018-11-15

Therapeutic compounds for pain and synthesis thereof

#155
20180291024
2018-10-11

Therapeutic compounds for pain and synthesis thereof

#156
20180282333
2018-10-04

2,11-diaza-[3.3](2,6)pyridinophane compounds and their application as ligands of essential metal ion based MRI contrast agents and 52MN based PET contrast agents

#157
20180222907
2018-08-09

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

#158
20180194766
2018-07-12

Macrocyclic ligands with pendant chelating moieties and complexes thereof

#159
20180186795
2018-07-05

Pyrimidinones as factor XIa inhibitors

#160
20180179198
2018-06-28

Tricyclic modulators of TNF signaling

#161
20180148442
2018-05-31

Polycyclic indoline and indolenine compounds

#162
20180133219
2018-05-17

BIHETEROARYL COMPOUNDS AND USES THEREOF

#163
20180118765
2018-05-03

Heterocyclic compounds and their use in preventing or treating bacterial infections

#164
20180117044
2018-05-03

BIHETEROARYL COMPOUNDS AND USES THEREOF

#165
20180086762
2018-03-29

Beta-lactamase inhibitors

#166
20180044338
2018-02-15

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

#167
20180024144
2018-01-25

Indole and indoline derivatives and methods of use thereof

#168
20180022753
2018-01-25

Macrocycles as factor XIa inhibitors

#169
20180009820
2018-01-11

Imidazole derivative used as antiviral agent and use thereof in preparation of medicament

#170
20170362234
2017-12-21

Substituted bridged urea analogs as sirtuin modulators

#171
20170355705
2017-12-14

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

#172
20170355697
2017-12-14

Substituted bridged urea analogs as sirtuin modulators

#173
20170342071
2017-11-30

MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES

#174
20170334923
2017-11-23

Opioid receptor modulators

#175
20170305932
2017-10-26

Fused pentacyclic imidazole derivatives

#176
20170283422
2017-10-05

Pyrimido-diazepinone compounds and methods of treating disorders

#177
20170267695
2017-09-21

ERK inhibitors

#178
20170260204
2017-09-14

Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections

#179
20170210743
2017-07-27

HDAC6 inhibitors and their uses

#180
20170190737
2017-07-06

Macrocyclic inhibitors of flaviviridae viruses

#181
20170137425
2017-05-18

Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

#182
20170129892
2017-05-11

Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

#183
20170107220
2017-04-20

Azamorphinan derivatives and use thereof

#184
20170096429
2017-04-06

Macrocycles with aromatic P2′ groups as factor xia inhibitors

#185
20170088550
2017-03-30

P2X7 modulators

#186
20170066770
2017-03-09

Therapeutic compound for pain and synthesis thereof

#187
20170066769
2017-03-09

Therapeutic compounds for pain and synthesis thereof

#188
20170066768
2017-03-09

Therapeutic compounds for pain and synthesis thereof

#189
20170066767
2017-03-09

Therapeutic compounds for pain and synthesis thereof

#190
20170066760
2017-03-09

Therapeutic compounds and synthesis

#191
20170057961
2017-03-02

MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES

#192
20170002006
2017-01-05

MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS

#193
20160372684
2016-12-22

Donor-acceptor nanohoop compounds and methods of making and using the same

#194
20160368923
2016-12-22

PYRIMIDINONES AS FACTOR XIA INHIBITORS

#195
20160362414
2016-12-15

Macrocycles as factor XIa inhibitors

#196
20160340360
2016-11-24

Dihydropyridone P1 as factor XIa inhibitors

#197
20160318943
2016-11-03

Imidazole derivative used as antiviral agent and use therof in preparation of medicament

#198
20160318932
2016-11-03

Pyridone-sulfone morphinan analogs as opioid receptor ligands

#199
20160304531
2016-10-20

Macrocyclic deaza-purinones for the treatment of viral infections

#200
20160304517
2016-10-20

Tricyclic modulators of TNF signaling

#201
20160285009
2016-09-29

Organic Electroluminescent materials and devices

#202
20160226003
2016-08-04

Heterocyclic compounds

#203
20160194335
2016-07-07

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#204
20160137914
2016-05-19

Electrochromic iptycenes

#205
20160096839
2016-04-07

Pyrimidinones as factor XIa inhibitors

#206
20160083386
2016-03-24

Substituted bridged urea analogs as sirtuin modulators

#207
20160060259
2016-03-03

Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them

#208
20160052940
2016-02-25

Biheteroaryl compounds and uses thereof

#209
20160039836
2016-02-11

P2X7 modulators

#210
20160024115
2016-01-28

Pyrimido-diazepinone compounds and methods of treating disorders

#211
20150353550
2015-12-10

INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF

#212
20150335654
2015-11-26

Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use

#213
20150315188
2015-11-05

COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION

#214
20150315145
2015-11-05

PROCESS FOR PRODUCING OPTICALLY ACTIVE BICYCLIC UREA COMPOUND

#215
20150274774
2015-10-01

Macrocyclic inhibitors of flaviviridae viruses

#216
20150266896
2015-09-24

Production of polyketides and other natural products

#217
20150266894
2015-09-24

Macrocycles as factor XIa inhibitors

#218
20150266884
2015-09-24

Compounds and methods for treatment of hypertension

#219
20150259346
2015-09-17

Hexahydrodiazepinoquinolines carrying a substituted alkyl radical

#220
20150209452
2015-07-30

Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease

#221
20150203494
2015-07-23

Pyridonemorphinan analogs and biological activity on opioid receptors

#222
20150203492
2015-07-23

Dihydropyridone p1 as factor XIa inhibitors

#223
20150166541
2015-06-18

Azaadamantane formate ester and process for preparing azaadamantane derivatives

#224
20150158867
2015-06-11

AZAADAMANTANE DERIVATIVES AND METHODS OF USE

#225
20150152108
2015-06-04

Substituted bridged urea analogs as sirtuin modulators

#226
20150126514
2015-05-07

Bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

#227
20150112058
2015-04-23

Macrocycles as factor XIa inhibitors

#228
20150110805
2015-04-23

THERAPEUTIC STRATEGY FOR TREATING AUTOIMMUNE AND DEGENERATIVE DISEASES

#229
20150018359
2015-01-15

Substituted pyrido[1′,2′:4,5]pyrazino[1,2-a]azepines for treating viral infections

#230
20150018298
2015-01-15

Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

#231
20150005492
2015-01-01

Stereoselective total synthesis of noribogaine

#232
20150005322
2015-01-01

Pyrido[3,4-b] indoles and methods of use

#233
20140330009
2014-11-06

Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them

#234
20140328805
2014-11-06

Biheteroaryl compounds and uses thereof

#235
20140296209
2014-10-02

Compounds and methods for treatment of hypertension

#236
20140275546
2014-09-18

Azaadamantane formate ester and process for preparing azaadamantane derivatives

#237
20140275056
2014-09-18

5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators

#238
20140221356
2014-08-07

Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections

#239
20140187549
2014-07-03

Pyridonemorphinan analogs and biological activity on opioid receptors

#240
20140186969
2014-07-03

Dinitroxide-type biradical compounds optimized for dynamic nuclear polarization (DNP)

#241
20140179669
2014-06-26

Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use

#242
20140171461
2014-06-19

Nitrogen containing morphinan derivatives and the use thereof

#243
20140155386
2014-06-05

Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

#244
20140155384
2014-06-05

COMPOUNDS AND METHODS OF TREATING DIABETES

#245
20140128400
2014-05-08

Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors

#246
20140128365
2014-05-08

PYRIDONE/HYDROXYPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

#247
20140088086
2014-03-27

Compounds and methods for treatment of hypertension

#248
20140024643
2014-01-23

Bridged heterocyclic compounds and methods of use

#249
20130344029
2013-12-26

Macrocyclic inhibitors of flaviviridae viruses

#250
20130296330
2013-11-07

MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS

#251
20130281389
2013-10-24

Drug targets to overcome de novo drug-resistance in multiple myeloma

#252
20130217675
2013-08-22

Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use

#253
20130210803
2013-08-15

Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use

#254
20130190344
2013-07-25

Pyrido[4,3-B]indoles and methods of use

#255
20130190308
2013-07-25

Pyrido[3,4-B]indoles and methods of use

#256
20130190303
2013-07-25

Bridged heterocyclic compounds and methods of use

#257
20130190294
2013-07-25

Compounds and methods for treating diabetes

#258
20130190293
2013-07-25

Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use

#259
20130184304
2013-07-18

Pyrido[4,3-B]indoles and methods of use

#260
20130184303
2013-07-18

PYRIDO[4,3-B]INDOLES AND METHODS OF USE

#261
20130184269
2013-07-18

Bridged heterocyclic compounds and methods of use

#262
20130172366
2013-07-04

Bridged heterocyclic compounds and methods of use

#263
20130172320
2013-07-04

PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE

#264
20130165647
2013-06-27

Stereoselective total synthesis of noribogaine

#265
20130165425
2013-06-27

Sulfate esters of noribogaine

#266
20130096132
2013-04-18

Azaadamantane derivatives and methods of use

#267
20130065875
2013-03-14

Small molecule inhibitors of hepatitis C virus

#268
20130053379
2013-02-28

4-aryl-2-anilino-pyrimidines

#269
20130053367
2013-02-28

Compounds and methods of treating diabetes

#270
20130053366
2013-02-28

Compounds and methods for treatment of hypertension

#271
20130018051
2013-01-17

Bridged bicyclic heteroaryl substituted triazoles useful as inhibitors

#272
20120309960
2012-12-06

Macrocycles as factor XIa inhibitors

#273
20120196890
2012-08-02

4-SUBSTITUTED AZAADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF

#274
20120190706
2012-07-26

ACETAMIDE AND CARBOXAMIDE DERIVATIVES OF AZAADAMANTANE AND METHODS OF USE THEREOF

#275
20120190704
2012-07-26

AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF

#276
20120172367
2012-07-05

Macrocyclic integrase inhibitors

#277
20120172350
2012-07-05

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

#278
20120165313
2012-06-28

PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

#279
20120065219
2012-03-15

SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE

#280
20120053171
2012-03-01

Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors

#281
20120046298
2012-02-23

Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

#282
20120041190
2012-02-16

Macrocycles as factor XIa inhibitors

#283
20120035102
2012-02-09

AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF

#284
20120022045
2012-01-26

BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS

#285
20110281846
2011-11-17

Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as Axl inhibitors

#286
20110275581
2011-11-10

Nuclear export inhibitors of topoisomerase II alpha

#287
20110269791
2011-11-03

Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use

#288
20110245272
2011-10-06

Pyrido[4,3-b]indoles and methods of use

#289
20110237582
2011-09-29

Pyrido[3,4-B]indoles and methods of use

#290
20110212943
2011-09-01

NOVEL BRIDGED CYCLIC COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

#291
20110183986
2011-07-28

Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors

#292
20110178119
2011-07-21

Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase

#293
20110165633
2011-07-07

Production of polyketides and other natural products

#294
20110152306
2011-06-23

AZA-bridged ring-fused indoles and indolines

#295
20110152248
2011-06-23

Bridgehead amine ring-fused indoles and indolines

#296
20110112122
2011-05-12

Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT) modulators and uses thereof

#297
20110105512
2011-05-05

Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors

#298
20110077264
2011-03-31

Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics

#299
20110065694
2011-03-17

Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof

#300
20110039832
2011-02-17

(Dihydro)pyrrolo[2,1-α]isoquinolines